MedTrace Logo

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

NCT06924320 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2026-02-03

No results posted yet for this study

Summary

This study is designed to test how well the combination of MET233 with MET097 works to treat individuals with obesity or overweight with or without diabetes.

Conditions

  • Obesity and Obesity-related Medical Conditions

Interventions

DRUG

MET233 and MET097

For subcutaneous administration

DRUG

Placebo

Sterile 0.9% (w/v) saline for subcutaneous administration.

DRUG

MET233

For subcutaneous administration

Sponsors & Collaborators

  • Metsera, a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2027-01-25
Completion
2027-03-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06924320 on ClinicalTrials.gov